Loading...

APC anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_APC_1_082911
Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) PE, and then intracellularly stained with CD206 (clone C068C2) APC (top) or rat IgG2a, κ APC isotype control (bottom).
  • C068C2_APC_1_082911
    Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) PE, and then intracellularly stained with CD206 (clone C068C2) APC (top) or rat IgG2a, κ APC isotype control (bottom).
  • C068C2_APC_2_082911
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
141707 25 µg 105€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
141708 100 µg 237€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wang C, et al. 2018. J Pharmacol Exp Ther. 365:72. PubMed
  2. Miki H, et al. 2020. J Immunol. 204:1892. PubMed
  3. Zhou Y, et al. 2022. Br J Pharmacol. 179:1978. PubMed
  4. Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed
  5. Chang S, et al. 2022. Phytother Res. 36:1678. PubMed
  6. Tu J, et al. 2022. Cancer Sci. 113:2496. PubMed
  7. Wu J, et al. 2023. Bioact Mater. 20:259. PubMed
  8. Poh AR, et al. 2022. Sci Adv. 8:eabl7882. PubMed
  9. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  10. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  11. Lin J, et al. 2022. Eur J Histochem. 67: . PubMed
  12. Sun J, et al. 2023. Mediators Inflamm. 2022:1108569. PubMed
  13. Ye Z, et al. 2023. Front Med (Lausanne). 9:1075465. PubMed
  14. De Schepper S, et al. 2023. Nat Neurosci. 26:406. PubMed
  15. Kimura Y, et al. 2023. Front Immunol. 14:1070196. PubMed
  16. Liang P, et al. 2022. Prostate Cancer Prostatic Dis. 25:539. PubMed
  17. Gao T, et al. 2022. Cell Biochem Biophys. 80:579. PubMed
  18. Jia DJ, et al. 2022. Gut Microbes. 14:2145843. PubMed
  19. Song X, et al. 2022. Int J Mol Sci. 23:. PubMed
  20. Wu Y, et al. 2023. Adv Mater. 35:e2210787. PubMed
  21. Sheng Y, et al. 2023. Cancers (Basel). 15:. PubMed
  22. Wang Y, et al. 2023. Front Bioeng Biotechnol. 11:1128268. PubMed
  23. Kaur N, et al. 2023. Heliyon. 9:e14952. PubMed
  24. Lu Y, et al. 2023. J Transl Med. 21:339. PubMed
  25. Zhang Y, et al. 2023. NPJ Regen Med. 8:28. PubMed
  26. Yokozeki Y, et al. 2021. Biomed Res Int. 2021:7988320. PubMed
  27. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  28. Liu J, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.139. PubMed
  29. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
  30. Kiepura A, et al. 2021. Int J Mol Sci. 22:. PubMed
  31. Poh AR, et al. 2017. Cancer Cell. 31:563. PubMed
  32. Liu C, et al. 2019. J Transl Med. 17:300. PubMed
  33. Zhang X, et al. 2017. J Cell Mol Med. 10.1111/jcmm.13329. PubMed
  34. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  35. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  36. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  37. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  38. Jeong J, et al. 2017. Sci Rep. 7:39848. PubMed
  39. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  40. Chang CF, et al. 2017. Neurobiol Dis. 103:54. PubMed
  41. Pilch Z, et al. 2018. Cancer Immunol Res. 6:930. PubMed
  42. Zhang J, et al. 2021. Front Cardiovasc Med. 8:737652. PubMed
  43. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  44. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  45. Adachi Y, et al. 2022. Nat Commun. 13:5117. PubMed
  46. Giordano C, et al. 2014. Hum Mol Genet. . PubMed
  47. Mylonas K, et al. 2015. Immunobiology. 220: 924-933. PubMed
  48. Cardona S, et al. 2015. ASN Neuro. 7: 1759091415608204. PubMed
  49. Tahiri H, et al. 2016. Sci Rep. 6:37391. PubMed
  50. Nawaz A, et al. 2022. Nat Commun. 13:7058. PubMed
  51. Zhang L, et al. 2022. Acta Pharm Sin B. 12:3427. PubMed
  52. Chen X, et al. 2021. Cell Death Differ. 28:1237. PubMed
  53. Trott DW, et al. 2021. Geroscience. 43:1331. PubMed
  54. Yuan Q, et al. 2021. Cell Reports. 34(5):108724. PubMed
  55. Young JA, et al. 2020. Journal of Neuroendocrinology. e12854.. PubMed
  56. Shang W, et al. 2019. J Diabetes Res. 2019:5641271. PubMed
  57. Li S, et al. 2021. Ann Transl Med. 9:1644. PubMed
  58. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  59. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  60. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  61. Li Q, et al. 2021. Brain Behav Immun. 94:437. PubMed
  62. Wada N, et al. 2020. Mol Metab. 37:100988. PubMed
  63. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  64. Motoyama S, et al. 2020. Cells. :9. PubMed
  65. Mariani SA, et al. 2019. Immunity. 50:1439. PubMed
  66. Yan J, et al. 2018. Nat Commun. 9:33. PubMed
  67. Kan C, et al. 2022. Bone Res. 10:62. PubMed
  68. Liao Y, et al. 2020. Mol Ther. 28:855. PubMed
  69. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  70. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  71. Qiu J, et al. 2016. Sci Rep. 6:39407. PubMed
  72. Lasky C, et al. 2015. Infect Immun . 83: 2627 - 2635. PubMed
  73. van Dierendonck XAMH, et al. 2020. Cell Reports. 30(6):1811-1822. PubMed
  74. Chen X, et al. 2022. J Appl Oral Sci. 30:e20220316. PubMed
  75. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  76. Xie Z, et al. 2021. Open Life Sci. 16:653. PubMed
  77. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  78. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  79. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  80. Xiao Y, et al. 2022. Clin Transl Med. 12:e1071. PubMed
  81. Feng T, et al. 2022. Nat Commun. 13:5208. PubMed
  82. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  83. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  84. Taguchi K, et al. 2015. J Urol. . PubMed
  85. Calvo B, et al. 2020. IBRO Rep. 8:36. PubMed
  86. Jin RM, et al. 2017. J Immunol. 198:352. PubMed
  87. Mallampalli RK, et al. 2021. Front Immunol. 12:735576. PubMed
  88. Rios-Doria J, et al. 2021. Front Oncol. 10:598477. PubMed
  89. Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed
  90. Ayala TS, et al. 2019. Sci Rep. 9:11447. PubMed
  91. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  92. Wang Q, et al. 2018. Nat Commun. 9:559. PubMed
  93. Xu M, et al. 2022. Genes Dis. 9:429. PubMed
  94. Ganesan R, et al. 2020. FASEB J. 34:15888. PubMed
  95. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  96. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  97. Xue N, et al. 2017. Sci Rep. 7:39011. PubMed
  98. Lee JY, et al. 2020. Nat Commun. 11:2358. PubMed
  99. Yoon J, et al. 2020. Front Cell Dev Biol. 0.520138889. PubMed
  100. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  101. Sasaki T, et al. 2020. Cell Reports. 28(1):202-217.e7.. PubMed
  102. Zhou X, et al. 2022. Front Pharmacol. 13:872188. PubMed
  103. De Simone G, et al. 2021. Immunity. :. PubMed
  104. Moya-Pérez A, et al. 2015. PLoS One. 10: 0126976. PubMed
  105. Luo J et al. 2018. Immunity. 49(1):107-119 . PubMed
  106. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  107. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  108. Zhang S, et al. 2021. J Inflamm Res. 14:4915. PubMed
  109. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  110. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  111. Blriot C, et al. 2021. Immunity. :. PubMed
  112. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  113. Yamakawa D, et al. 2021. Cell Reports. 34(10):108817. PubMed
  114. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  115. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  116. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  117. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  118. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  119. Trott DW, et al. 2021. J Physiol. 599:3973. PubMed
  120. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  121. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  122. Remmerie A, et al. 2020. Immunity. 53:641. PubMed
  123. Quenum Zangbede FO, et al. 2018. J Neurosci. 38:6737. PubMed
  124. Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed
  125. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  126. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  127. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  128. Dong R, et al. 2021. Frontiers in Immunology. 12:620238. PubMed
  129. Zhang Y, et al. 2020. Mol Med Rep. 22:534. PubMed
  130. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  131. Gao Z, et al. 2022. J Inflamm Res. 15:3337. PubMed
  132. Dai K, et al. 2015. J Leukoc Biol. 98: 1071 - 1080. PubMed
  133. Settelmeier S, et al. 2020. PLoS One. 15:e0233261. PubMed
  134. He H, et al. 2012. Blood. 120:3152. PubMed
  135. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  136. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  137. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  138. Canedo T, et al. 2021. Neuropsychopharmacology. 46:2358. PubMed
  139. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  140. Roux C, et al. 2021. Antioxidants (Basel). 10:. PubMed
  141. Li K, et al. 2020. J Cell Mol Med. 24:13115. PubMed
  142. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  143. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  144. Lee SH, et al. 2018. J Exp Med. 215:357. PubMed
  145. Tang PC, et al. 2022. Adv Sci (Weinh). 9:e2101235. PubMed
  146. Cui Y, et al. 2022. Front Oncol. 12:732860. PubMed
  147. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  148. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  149. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  150. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  151. Piirainen S, et al. 2021. Glia. 69:2459. PubMed
  152. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  153. Zhu Y, et al. 2021. Int J Oral Sci. 13:25. PubMed
  154. Filtjens J, et al. 2021. Nat Commun. 12:2936. PubMed
  155. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  156. Canan C, et al. 2014. J Leukoc Biol. 96:473. PubMed
  157. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  158. Baardman J et al. 2018. Cell reports. 25(8):2044-2052 . PubMed
  159. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  160. Durga Devi T, et al. 2017. Am J Pathol. 187:2659. PubMed
  161. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  162. Song HY, et al. 2021. Mol Ther. S1525-0016:00472-X. PubMed
  163. Kurelac I, et al. 2019. J Clin Med. 1.85. PubMed
  164. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  165. Syed I et al. 2018. Cell metabolism. 27(2):419-427 . PubMed
  166. Nasti A, et al. 2017. Eur J Immunol. 47:2163. PubMed
  167. Chithanathan K, et al. 2022. Biology (Basel). 11:. PubMed
  168. Ding T, et al. 2021. J Nanobiotechnology. 19:247. PubMed
  169. Andreata F, et al. 2021. STAR Protoc. 2:100831. PubMed
  170. Liu Y, et al. 2019. Am J Physiol Cell Physiol. 317:C762. PubMed
RRID
AB_10896057 (BioLegend Cat. No. 141707)
AB_10900231 (BioLegend Cat. No. 141708)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
UniProt
View information about CD206 on UniProt.org

Related FAQs

Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Other Formats

View All CD206 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 711™ anti-mouse CD206 (MMR) C068C2 ICFC,FC
Brilliant Violet 785™ anti-mouse CD206 (MMR) C068C2 ICFC,FC
PE/Dazzle™ 594 anti-mouse CD206 (MMR) C068C2 ICFC,FC
Alexa Fluor® 700 anti-mouse CD206 (MMR) C068C2 ICFC,FC
Spark YG™ 570 anti-mouse CD206 (MMR) C068C2 IHC-F
Biotin anti-mouse CD206 (MMR) C068C2 ICFC,FC
FITC anti-mouse CD206 (MMR) C068C2 ICFC,FC
PE anti-mouse CD206 (MMR) C068C2 ICFC,FC
APC anti-mouse CD206 (MMR) C068C2 ICFC,FC
Alexa Fluor® 488 anti-mouse CD206 (MMR) C068C2 ICFC,FC,IHC-F
Alexa Fluor® 647 anti-mouse CD206 (MMR) C068C2 ICFC,FC,IHC-F
Purified anti-mouse CD206 (MMR) C068C2 ICFC,FC
PerCP/Cyanine5.5 anti-mouse CD206 (MMR) C068C2 ICFC,FC
PE/Cyanine7 anti-mouse CD206 (MMR) C068C2 ICFC,FC
Brilliant Violet 605™ anti-mouse CD206 (MMR) C068C2 ICFC,FC
Brilliant Violet 650™ anti-mouse CD206 (MMR) C068C2 ICFC,FC
Brilliant Violet 421™ anti-mouse CD206 (MMR) C068C2 ICFC,FC,IHC-F,SB
Alexa Fluor® 594 anti-mouse CD206 (MMR) C068C2 IHC-F
PE/Cyanine5 anti-mouse CD206 (MMR) C068C2 ICFC,FC
PE/Fire™ 700 anti-mouse CD206 (MMR) C068C2 ICFC,FC
TotalSeq™-B0173 anti-mouse CD206 (MMR) C068C2 ICPG
Spark Red™ 718 anti-mouse CD206 (MMR) (Flexi-Fluor™) C068C2 FC
Spark Blue™ 574 anti-mouse CD206 (MMR) (Flexi-Fluor™) C068C2 FC
TotalSeq™-C0173 anti-mouse CD206 (MMR) Antibody C068C2 ICPG
Spark YG™ 581 anti-mouse CD206 (MMR) (Flexi-Fluor™) C068C2 FC
Spark YG™ 593 anti-mouse CD206 (MMR) (Flexi-Fluor™) Antibody C068C2 FC
Spark NIR™ 685 anti-mouse CD206 (MMR) (Flexi-Fluor™) Antibody C068C2 FC
Go To Top Version: 3    Revision Date: 04.04.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account